Logo

Larimar Therapeutics, Inc.

LRMR

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.ā€ā€ā€Žā€¦ read more

Healthcare

Biotechnology

9 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$3.83

Price

+18.42%

$0.60

Market Cap

$327.383m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$482k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$99.786m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.56

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$119.854m

$149.988m

Assets

$30.134m

Liabilities

$4.614m

Debt
Debt to Assets

3.1%

-

Debt to EBITDA
Free Cash Flow

-$92.591m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases